Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Herantis Pharma, Webcast, Full Year Report 2025 January – December 2025

By Inderes3/5/2026, 8:00 AM
Herantis Pharma

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Antti Vuolanto
00:01 - 07:07

Good morning and welcome to Herantis Pharma Plc full year 2025 results webcast and business update. My name is Antti Vuolanto. I'm the CEO, and together with me I have here our CFO, Tone Kvåle. During the webcast, we will review the key highlights of the past year and provide you an update of the business and R&D. After the presentation, we have a Q&A session and you are welcome to submit questions throughout the webcast. With that, let's get started. And first, the necessary forward-looking statements. And then a short reminder of what Herantis Pharma Plc is. And then we go into the last year's highlights. So Herantis Pharma Plc, we are a clinical-stage public company listed here in Nasdaq First North Growth Market, Finland. And with our lead asset, HER-096, we aim to stop the progression of Parkinson's disease by protecting dopamine neurons from further degeneration and also support their functional restoration. We have just announced that we have completed a Phase 1 program. We have solid safety data. We have shown efficient brain penetration. We have strong biomarker data showing biological response in Parkinson's patients. We are ready to start a Phase 2 efficacy signal-finding trial. So, just a reminder, what HER-096 is, it is a first-in-class peptide targeting key drivers of Parkinson's disease, specifically modulation of the unfolded protein response pathway. So Proteostasis and we have also shown a robust impact on mitochondrial function as well. HER-096 design is based on a protein, a neurotrophic factor called CDNF or cerebral dopamine neurotrophic factor, and we have shown in pre-clinical settings that yes, we capture the full activity of the CDNF protein in terms of protection of the neurons and supporting the neurons for functional recovery. So if we think about the clinical and therapeutic profile of HER-096, we do have a disease modifying and symptomatic potential based on pre-clinical studies and earlier studies with CDNF protein. So we can slow or even halt the neurodegeneration in the midbrain, which is relevant for Parkinson's disease. As already mentioned, we have a biological validation with the biomarker data from Parkinson's patients. We have robustly confirmed brain penetration after subcutaneous administration. So we believe that we have all the ingredients that HER-096 can really be a game-changing therapy. That could really stop the progression of Parkinson's disease, which currently is not possible. So there is an unmet clinical need in the disease. The current treatments can treat the symptoms but not the disease itself. And many patients don't get a symptomatic benefit. Or they might have significant side effects. And also, the effectiveness of the current treatments declines over time as the disease progresses in the background, regardless of their application. And of course, as a consequence of that, there is a huge market potential for HER-096. HER-096. Parkinson's News Today is an organization that has evaluated that the estimated economic impact of Parkinson's disease globally is around 277 billion USD annually. So it's a huge impact on societies. It's forecasted that the therapeutic market in PD will grow to 13 billion USD by 2033. This is from GlobalData. And there are also estimates that from the currently approximately 10 million patients until 2050, there will be 25 million patients. So we are in the middle of a very large unmet clinical need, and we want to be among the first ones to really address this. So this was the short introduction to this. And let's go into the highlights of 2025. So I'll start this with the business highlights. So a year ago, on February 25th, we announced that we successfully completed a directed share issue. We raised €5.2 million, and that was obviously used for finalising the Phase 1b and being able to deliver the great data. We announced the top line data from the Phase 1 trial with Parkinson's disease patients in October. The trial met all its primary and secondary endpoints. So we demonstrated a very nice safety profile and also the robust brain penetration in Parkinson's patients' brains. In November, we announced that we have completed a six-month preclinical toxicology study with HER-096. And this is, of course, a major milestone towards being ready for a Phase 2 trial, as this kind of a long-term preclinical study is a prerequisite for starting a long Phase 2 efficacy trial. And right after the reporting period, we have also provided a lot of good news. So in early January, we reported the biomarker data showing that we have very clear evidence of biological response to HER-096 exposure in Parkinson's disease patients. In early February, we announced a directed share issue. We raised €4.2 million. And further, in February, we announced that we have been selected for an €8 million Horizon Europe Grant that will be used for supporting the conduct of the Phase 2 clinical trial. But let's go into the financial figures, and Tone Kvåle will go through those.

Tone Kvåle
07:08 - 09:31

Thank you. So full year 2025 compared to last year. The total operating expenses remained at the same level. But the difference you can see on the loss side is that in 2024 we had the EIC Accelerator grant program which ended in 2025. So we got more grant in 2024 compared to 2025. Most of the money we are spending goes directly to science. We spent it on finalizing the Phase 1b trial. We are also preparing for the Phase 2. And the development of biomarkers is also a big part of the costs. And then last year, we raised money in February 2025, and we had finance expenses relating to that. And we are continuing the focus on investor relations and partnering activities. So when it comes to the cash, we ended the year with 2.6 million in the bank, compared to 2.1 in 2024. Right after we closed the books, we had a successful fundraising that raised gross $4.2 million. With the cash we have as of today, it takes us into Q1 2027. So, to be able to start the Phase 2 clinical trial, we need to raise more money. So for the financial position, just going through some of the balance sheet items for 2025, if you look into the balance sheet, you see that the long-term debt increased from $2.1 million in 2024 to $3.4 million in 2025, and that is due to the research funding which we are receiving from Michael J. Fox and Parkinson's UK. By the end of the year, we had a temporary negative equity of €1.7 million, but that went positive when we raised the money in February. But we had a temporary negative equity of 1.7 by the end of the year, which went positive when we raised the money in February. And as Antti mentioned, for the financial events, we had the successful fundraising and also we were selected for the €8 million grant from Horizon Europe, which is going to be spent on running the Phase 2 trial. So that's really good that we have the cash coming in.

Antti Vuolanto
09:33 - 21:49

Very good. Most of the money goes directly to the science. And let's move on with the short business update. So as mentioned, we have a completed Phase 1 program. Just a short recap of what the Phase 1 program told us and what will be the next steps. So the Phase 1a clinical trial that we completed a couple of years ago was a single ascending dose study in healthy individuals. And we also had elderly individuals there to take cerebrospinal fluid samples to show the brain penetration profile of HER-096. And the main findings were very good safety and tolerability profile of the single dose. We demonstrated efficient brain penetration in elderly, healthy individuals. And the brain penetration was very much aligned with the preclinical findings. We had reported earlier. And we also have very favorable pharmacokinetic profile considering the administration. And now we completed a Phase 1 clinical trial where we first had a couple of additional elderly individuals for single administration to complete some of the pharmacokinetic work. Then we had Parkinson's patients in two cohorts with two dose levels, 200 mg and 300 mg doses, and placebo patients as well. And these patients received HER-096 or placebo treatment for four weeks. Two administrations per week. The main findings continued to show a good safety and tolerability profile in Parkinson's patients. We established the pharmacokinetics in the cerebrospinal fluid in these patients. And, of course, a biological response was observed in biomarker analysis, which I will provide further insight into here, along with a recap of the webinar we held in early January. About the safety profile. Here is a very high-level summary of the systemic safety findings from patients or healthy individuals receiving HER-096 dosing. So, on the systemic level, we didn't see any treatment-emergent adverse events, no serious adverse events, and no dose-limiting toxicities. And we didn't reach, obviously, the maximum tolerated dose. And this was very much aligned with the preclinical studies. The main incidence that we saw was related to the injection site. It was mild, transient, and self-resolving, exactly aligned with preclinical findings. And this is of course very good. And then the second part of the results is obviously the presence of HER-096 in the cerebrospinal fluid. And this data summarizes what we learned from the Parkinson's patients in the Phase 1b with 200 mg dose. We ended up close to 100 nanograms per mL; with the 300mg dose, close to 150 nanograms per mL. And again, this is very much aligned with the preclinical data. And these levels are comparable to those levels that we have seen in preclinical settings to provide the maximum efficacy in those models. So we believe that 300mg dose will be a very good dose for going forward with Phase 2. And this is also supported by the biomarker data. And just a short recap of what did we see in the biomarker data. And just a reminder that we analyzed different sample types with different technologies. But the main comparison was the change that we observed when we compared the before dosing sample of the last dose to the before dosing sample of the first dose. So a cumulative effect of four weeks exposure to HER-096. So we had samples from CSF. So demonstrating what happens in the CNS. And there we showed an effect on proteostasis and oxidative stress and inflammation. So, it is closely related to the Unfolded Protein Response pathway and mitochondrial function. Then we had samples that are called neuronal-enriched extracellular vesicles. So particles that come from the central nervous system. The sample is taken from the blood. So we can't say for sure that all the signals come from the CNS. But maybe the majority of that. And again, we see changes in mitochondrial functions and also inflammation, very much aligned with the mechanism of action. And then from plasma and blood. We also saw changes in proteostasis and in mitochondrial functions. So these are multiple layers of data showing very concordant results across different sample types. Different locations where we derive the samples show that there is a very clear biological response. And this is a true response in Parkinson's patients. And the response is aligned with the mechanism of action. So if I summarize in one slide what we see. At baseline, Parkinson's patients have a chronically activated unfolded protein response pathway. So there is. Dysfunction of proteostasis. There is also a lower activity of mitochondrial function. So Mitochondria are the energy factories of the cell. And there is elevated oxidative stress. So overall, the stress level is high, and cellular viability and function are low. After HER-096 dosing, we see elevation of proteostasis activity. We see elevation of mitochondrial function. We see a decrease in oxidative stress. So we have decreased the stress and increased the viability functionality. And then of course the very good question is, as this is the data from the first month, what happens after a longer treatment period? And we of course believe and hope that it will result in symptomatic improvement and disease modification. And this is, of course, the purpose of running the Phase 2 trial to demonstrate this in Parkinson's patients, which would then allow going forward with the commercialization path. So if I summarize where we are with HER-096, we believe that we have reduced development risk based on the very successful Phase 1 trial. We have established. Very nice safety profile, confirmed brain penetration. We have biomarker confirmed biological activity. So we believe that we have much reduced translational risk. We are ready for Phase 2. So we are planning a signal seeking proof-of-concept efficacy trial in approximately 100 early-stage Parkinson's patients. It will be a multicenter European study if we run that ourselves, and we are currently nearing the confirmation of the study design; it's not completely ready yet. But we, of course, will inform the market when we are ready to do so. HER-096 is very much a differentiated asset. So it's a first-in-class peptide that we are focusing on. The Unfolded Protein Response pathway is being addressed. We are doing so as the only company in clinical development. With that, we target the core drivers of Parkinson's pathology. And we really have designed from the beginning the asset to really modify or stop the progression of the disease. And of course, what we are currently doing, we are looking at the different routes and options, how we can execute the Phase 2. And we are in discussions with strategic partners. We are in discussions with investors. We also confirmed the 8 million Horizon Europe grant that will support the conduct of the study. And we are also looking at different non-dilutive opportunities. There might also be other non-dilutive opportunities, but of course, we will inform the market as soon as we have anything material on this resourcing of the Phase 2 efficacy trial. I want to highlight the strong external validation and financial support that we have for HER-096. HER-096, Parkinson's UK, the Michael J. Fox Foundation financed the majority of the Phase 1 clinical trial with almost 4 million research financing. And we obviously continue to discuss with them how they could support the conduct of the Phase 2. We have also had very strong support from the European Union. We completed a biomarker development programme worth 2.5 million euros, and that was completed approximately a year ago. We have secured a 15 million investment commitment from EIC Fund, from which we have now utilised 4.2 million. So, over 10 million still remains in that commitment. And we just announced an €8 million EU grant to support the Phase 2 trial. So we have been quite successful in achieving this validation. And I have to highlight that all of these financiers and the financing are really competitive vehicles and opportunities. So we have been really happy that our science and the commercial potential have been evaluated to be really strong among these organizations. So as a summary, we believe that HER-096 is a potentially game-changing therapy that could become the first disease-modifying treatment for Parkinson's disease. We have a huge market opportunity. We are backed by strong research and robust external validation. And one thing that I didn't address yet is that the broad functionality of HER-096 in the basic biology of aging cells, improving the tolerance against different stress factors, may open wide therapeutic opportunities in other neurodegenerative disorders or even beyond CNS indications. By these words, I think we will end the business update and we are ready to start the Q&A session.

Tone Kvåle
21:50 - 22:04

We have received questions, and you can continue sending in questions via the webcast. The first one is can you provide an update of your Phase 2 plans? And when do you expect to initiate it?

Antti Vuolanto
22:05 - 23:37

Yes. So, as I mentioned, we are currently finalizing the study design. So we are also, in addition to that, considering regulatory preparation and regulatory discussions on the protocol. What we can say is that we are planning a double-blind, placebo-controlled, randomized efficacy and safety trial in early-stage Parkinson's patients. And we are engaged with several European top-notch investigators also within that EU consortium that won the grant, and of course, the recent fundraise helps us to prepare for the Phase 2 and also gives us the freedom to find the right financial ways of resourcing the Phase 2. And as mentioned, the trial will be most likely conducted within Europe. If we run that ourselves, however, we are making sure that we are also open, regulatory-wise, to be able to open trial sites elsewhere, for example, in the US, if there is a need, such as from a partner or an investor who would have an incentive to open up a site also elsewhere than in Europe.

Tone Kvåle
23:38 - 23:52

We have a huge market opportunity. Next one is regarding the Horizon grant. And congratulations with that. How will this impact the company from a strategic point of view and also from a financial point of view?

Antti Vuolanto
23:53 - 24:34

Yeah. Of course, 8 million for conduct of Phase 2. It decreases the capital need for running Phase 2 by the full amount of the grant. It is, of course, also very beneficial for our shareholders as that's non-dilutive. So I think that's great. But in addition to that, of course, Horizon Europe grants are really competitive grant vehicles. And being selected for the grant shows that, first of all, we have great science, but we also have great commercial opportunities there. And that brings a quality stamp as we were winning this grant.

Tone Kvåle
24:37 - 25:43

And one thing that I didn't address yet is that the broad functionality of HER-096 in the basic biology of aging cells, improving the tolerance against different stress factors, may open wide therapeutic opportunities in other neurodegenerative disorders or even beyond CNS indications. Next one is, based on your current cash position and the benefit from the grant. What additional capital do you need? And will be required to be able to start the Phase 2 trial? Maybe I can just take that one. As you know, we raised 4.2 million in February, and that will help us continue the preparation for the Phase 2. We got the Horizon Europe grant of 8 million, and that is earmarked for Phase 2. So of course, that is helping us a lot. But in addition, we think we need more; of course, we haven't yet completed all necessary steps. The final design of the trial is not ready yet, but we think, in the range between 20 and 25 million is needed as additional capital on top of this to fully fund the trial and also the ongoing operation during the trial period. Next one, Is the Phase 1b biomarker data good enough to secure a partnering agreement?

Antti Vuolanto
25:44 - 26:45

Well, that's a very good question. Of course, the full Phase 1 data package that we have, including the safety, pharmacokinetic, and biomarker data, is a great package. And when we have discussed this package within the partnering discussions or with other stakeholders like the patient organizations or informed investors, everybody congratulates that you could not get much more within a Phase 1 clinical program. However, it might not be appropriate to start speculating about exactly whether this could trigger a partnering agreement or not, because there are many different kinds of pharmaceutical companies. They have different objectives. And there might be different deal structures that we investigate, so of course we will inform the market as soon as there is something material. But before we have anything material, we cannot speculate too much.

Tone Kvåle
26:46 - 27:05

Yeah. Next question. Congratulations. With the FY 2025 progress, the Phase 1b biomarker analysis showed modulation of various Parkinson's disease-related pathways. How will these biomarker findings inform endpoint selection and patient stratification for Phase 2?

Antti Vuolanto
27:06 - 27:46

And what will be required to be able to start the Phase 2 trial? We are really happy that we have seen changes in the core pathways, including Proteostasis and mitochondrial function. Maybe for patient selection. The challenge is how we can exploit that data when screening patients, and we believe that we need to select early-stage patients. In Phase 2, we need to carefully design what is the primary endpoint, and then select the patients in such a way that they show characteristics that are measured by the primary endpoint. So that's the focus there.

Tone Kvåle
27:47 - 28:10

Good. I think there were no more questions. So maybe, some closing remarks. I think, from our side, we see that we have really strong external validation of our science during 2025. So I think the future looks good. What do you think?

Antti Vuolanto
28:11 - 29:31

Yeah, I fully agree. So I think 2025 was a very successful year. We were able to complete a fairly large clinical trial within the time and the budget, which is not always a given in clinical development. The data is great. We have a very good momentum. We have received really good feedback, and now we just need to move forward and ensure that we can run the Phase 2 clinical trial. And of course, within the Phase 2 trial, providing the first efficacy signal, that's the trial where value creation is potentially the quickest among clinical studies. So we look very positively forward to this year and what it will bring, and we hope to be able to update the market about the future development related to finalizing the Phase 2 clinical plan and also how we resource the trial within due course. So thank you for joining us today. Thank you for submitting the questions. And I hope you will follow us closely going forward. Thank you.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…